187 related articles for article (PubMed ID: 19860698)
1. PDE5 inhibitors in non-urological conditions.
Vlachopoulos C; Terentes-Printzios D; Ioakeimidis N; Rokkas K; Stefanadis C
Curr Pharm Des; 2009; 15(30):3521-39. PubMed ID: 19860698
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular effects of phosphodiesterase type 5 inhibitors.
Vlachopoulos C; Ioakeimidis N; Rokkas K; Stefanadis C
J Sex Med; 2009 Mar; 6(3):658-74. PubMed ID: 19138362
[TBL] [Abstract][Full Text] [Related]
3. [Novel indications for phosphodiesterase type 5 inhibitors].
Rosenkranz S; Caglayan E; Erdmann E
Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
[TBL] [Abstract][Full Text] [Related]
4. Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses.
Mostafa T
J Sex Med; 2008 Nov; 5(11):2502-18. PubMed ID: 18761597
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.
Ioakeimidis N; Kostis JB
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):53-64. PubMed ID: 24281316
[TBL] [Abstract][Full Text] [Related]
6. PDE5 inhibitors beyond erectile dysfunction.
Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
[TBL] [Abstract][Full Text] [Related]
7. Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders.
Samidurai A; Xi L; Das A; Kukreja RC
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():585-615. PubMed ID: 36206989
[TBL] [Abstract][Full Text] [Related]
8. PDE5 inhibitor treatment options for urologic and non-urologic indications: 2012 update.
Gur S; Kadowitz PJ; Serefoglu EC; Hellstrom WJ
Curr Pharm Des; 2012; 18(34):5590-606. PubMed ID: 22747425
[TBL] [Abstract][Full Text] [Related]
9. Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update.
Zhang WH; Zhang XH
Asian J Androl; 2016; 18(5):723-31. PubMed ID: 26620458
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
Corbin JD; Francis SH; Webb DJ
Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
[TBL] [Abstract][Full Text] [Related]
11. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
Corona G; Mondaini N; Ungar A; Razzoli E; Rossi A; Fusco F
J Sex Med; 2011 Dec; 8(12):3418-32. PubMed ID: 21995676
[TBL] [Abstract][Full Text] [Related]
13. PDE5 inhibitors: in vitro and in vivo pharmacological profile.
Kouvelas D; Goulas A; Papazisis G; Sardeli C; Pourzitaki C
Curr Pharm Des; 2009; 15(30):3464-75. PubMed ID: 19860692
[TBL] [Abstract][Full Text] [Related]
14. Current use of phosphodiesterase inhibitors in urology.
Hakky TS; Jain L
Turk J Urol; 2015 Jun; 41(2):88-92. PubMed ID: 26328208
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications.
Kumar P; Francis GS; Tang WH
Nat Rev Cardiol; 2009 May; 6(5):349-55. PubMed ID: 19377497
[TBL] [Abstract][Full Text] [Related]
16. PDE5 inhibitors: are there differences?
Carson CC
Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
[TBL] [Abstract][Full Text] [Related]
17. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
18. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.
Das A; Durrant D; Salloum FN; Xi L; Kukreja RC
Pharmacol Ther; 2015 Mar; 147():12-21. PubMed ID: 25444755
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease.
Nguyen H; Amanullah AM
Rev Cardiovasc Med; 2014; 15(2):158-67. PubMed ID: 25051133
[TBL] [Abstract][Full Text] [Related]
20. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
